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Abstract
We recently developed a novel tumor-targeted gene delivery system responding to hyperactivated intracellular
signals. Polymeric carrier for gene delivery consists of hydrophilic neutral polymer as main chains and cationic
peptide substrate for target enzyme as side chains, and was named polymer-peptide conjugate (PPC). Introduction
of chondroitin sulfate (CS), which induces receptor-medicated endocytosis, into polymers mainly with a high
cationic charge density such as polyethylenimine can increase tumor-targeted gene delivery. In the present study,
we examined whether introduction of CS into PPC containing five cationic amino acids can increase gene
expression in tumor cells. Size and zeta potential of plasmid DNA (pDNA)/PPC/CS complex were <200 nm and
between -10 and -15 mV, respectively. In tumor cell experiments, pDNA/PPC/CS complex showed lower stability
and gene regulation, compared with that of pDNA/PPC. Moreover, no difference in gene expression was identified
between positive and negative polymer. These results were caused by fast disintegration of pDNA/PPC/CS
complexes in the presence of serum. Thus, we suggest that introduction of negatively charged CS into polymers
with a low charge density may lead to low stability and gene regulation of complexes.
Introduction
Tumor-targeted gene delivery is beneficial for increasing
therapeutic effects and reducing the desired side effect.
These gene delivery systems are mainly based on passive
targeting and active targeting methods. Nanoparticles
pass through leaky, tortuous, and heterogeneous angio-
genic tumor blood vessels and tend to accumulate more
in tumors than in normal tissues showing a well-orga-
nized and functional structure. This phenomenon is
known as the enhanced permeability and retention effect
and is noteworthy as the passive targeting method.
Moreover, tumor cells exhibit several hyperactivated
receptors and cellular signals (protein kinases and pro-
teases) which play key roles on tumor growth and survi-
val and angiogenesis. Gene delivery systems recognizing
these hyperactivated receptors or cellular signals are the
main active targeting methods [1].
Recently, our group has proposed a novel drug or
gene delivery system responding to cellular signals and
developed some gene regulation systems corresponding
to the target protein kinases or proteases such as pro-
tein kinase A [2-4], caspase [5], Ikappa-B kinase [6],
human immunodeficiency virus-1 protease [7], and pro-
tein kinase C [8-12]. Carriers for delivery of genes con-
sisted of neutral and hydrophilic polymer as the main
chain and disease-specific peptide substrate as side
chains; we named polymer-peptide conjugates (PPC).
The disease-specific peptide substrates containing posi-
tive amino acids can bind anionic genes. Phosphoryla-
tion by protein kinases or cleavage by proteases leads to
disintegration of PPC/gene complexes and gene expres-
sion. Gene delivery systems recognizing hyperactivated
cellular signals show efficient disease-targeted gene
delivery.
Chondroitin sulfate (CS) is a negatively charged glyco-
saminoglycan containing two alternating monosacchar-
ides (N-acetylgalactosamine and glucuronic acid). It
recognizes a CD44 receptor, which is hyperactivated on
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cated endocytosis.
In the present study, we examined whether introduc-
tion of CS into pDNA/PPC complex can increase gene
expression in tumor cells. Diameter, zeta potential, and
stability of plasmid DNA (pDNA)/PPC/CS complexes
and their transfection efficiency for tumor cells were
elevated.
Results and discussion
PPC consisted of polyacrylamide as the main chain and
the peptide substrate as side chains. The content of pep-
tide as the side chains of the polymer was estimated to
be 2.9 mol% for the positive polymer [PPC(S)] contain-
ing the phosphorylation site serine (FKKQGSFAKKK)
and 2.8 mol% for the control negative polymer [PPC(A)]
that the serine in the peptide was substituted with ala-
nine (FKKQGAFAKKK) by using an elemental analysis,
respectively. Since the peptide substrate has five cationic
amino acids (lysine), it can bind to anionic pDNA. After
binding PPC with pDNA, CS was introduced into
pDNA/PPC complex.
We investigated whether PPC or PPC/CS can form a
stable complex with pDNA. When polymers were added
to the pDNA solution, the migration of pDNA was sup-
pressed during gel electrophoresis (Figure 1). This result
means that PPC or PPC/CS formed a stable complex
with pDNA through electrostatic interaction.
To find optical CS concentration, we determined zeta
potentials for several charge ratios of pDNA/PPC/CS.
Complexes became a plateau at a charge ratio 1:2:16 of
pDNA/PPC/CS, and their size and zeta potential were
178 nm and -12 mV, respectively (Figure 2). In this
study, we used pDNA/PPC/CS complex at a charge
ratio of 1:2:16.
Staining with WST-8 was used to identify cytotoxicity
of pDNA/PPC (charge ratio = 1:2) or pDNA/PPC/CS
(charge ratio = 1:2:16) complexes toward HepG2 cells.
Twenty-four hours after incubation with complexes, the
percentage of viable cells was calculated. The assay
results revealed that the complexes did not affect cell
viability (>90%) (data not shown).
To examine whether introduction of CS into pDNA/
PPC complex can increase gene expression in tumor
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Figure 1 Electrophoresis of pDNA alone, pDNA/PPC, or pDNA/PPC/CS complexes. Various concentrations of polymer were mixed with the
pDNA and analyzed by 1% agarose gel electrophoresis.
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Page 2 of 7cells, pDNA/PPC (charge ratio = 1:2) and pDNA/PPC/
CS (charge ratio = 1:2:16) complexes were transfected
into B16 melanoma and HepG2 cells. The pDNA/PPC/
CS complex showed lower gene expression in both
tumor cells, compared with that of pDNA/PPC com-
plex (Figure 3). In previous studies, for receptor-
mediated gene delivery, CS was introduced polymers
mainly with a high cationic charge density such as
polyethylenimine (PEI) [16,17]. On the other hand,
PPC carrier contains five cationic amino acids, mean-
ing that introduction of CS into pDNA/PPC complex
may make complexes weaken. Thus, we investigated
stability of pDNA/PPC and pDNA/PPC/CS complexes
in the presence of Opti-MEM or 10% fetal bovine
serum (FBS). The pDNA/PPC complex showed stable
diameters and light scattering intensity in Opti-MEM,
in the case of pDNA/PPC/CS complex, but their time-
dependent changes were observed (Figure 4). In the
presence of 10% FBS, both pDNA/PPC and pDNA/
PPC/CS complexes were disintegrated, but the speed
of disintegration was rapider in pDNA/PPC/CS than
pDNA/PPC complexes. These results indicate that
introduction of CS into pDNA/PPC complex makes
the complex weak and unstable.
Cationic polymers with a high cationic charge density
form stable complexes with gene and show high trans-
fection efficiency but have high cytotoxicity toward cells
and agglutination with blood components. Introduction
of CS into these polymers can reduce cytotoxicity and
agglutination and lead to receptor-mediated gene deliv-
ery [16,17]. However, there are very few evaluation stu-
dies for introduction of CS into polymers with a low
cationic charge density. Our study suggest that introduc-
tion of negatively charged CS into polymers with a low
charge density leads to low stability and gene regulation
of complexes.
A
B
Figure 2 (A) Diameter and (B) zeta potential of complexes. After binding PPC with pDNA, CS was added into pDNA/PPC complex in water.
Diameters and zeta potentials of the complexes were determined using a Zetasizer.
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pDNA/PPC/CS complex
PPC was synthesized as described previously [9]. Briefly,
acrylamide (41.2 mg, 581 μmol) and N-methacryloylpep-
tide (8.0 mg, 5.9 μmol), from which the methacryloyl
group attached to the amino terminus of the peptide,
were dissolved in water, degassed with nitrogen for 5
min, and then polymerized using ammonium persulfate
(3.9 mg, 17 mmol) and N,N,N’,N’,-tetramethylethylene-
diamine (5.1 μl, 34 mmol) as a redox couple at room
temperature for 90 min. The synthesized sample was
dialyzed against water overnight in a semi-permeable
membrane bag with a molecular weight cutoff of 50,000.
The dialyzed sample was lyophilized, and a final sample
was obtained as a white powder, which was used as the
polymer for PPC. The concentration of the peptide was
estimated by elemental analysis.
For making pDNA/PPC/CS complex, 20 μlo fp D N A
(pCMV-luciferase) (0.1 μg/μl) and 20 μl of PPC (640
μM) were mixed for 20 min at room temperature and
then incubated further for 20 min after addition of CS
(3.98 mM) into pDNA/PPC solution.
Measurements of zeta potential and diameter of
complexes
pDNA/PPC/CS complex solution at a charge ratio of
1:2:16 was adjusted to 1 ml by 10 mM HEPES buffer
(pH 7.3) or Opti-MEM (Gibco, Invitrogen Co., Grand
Island, NY, USA). The zeta potential and diameter of
the complexes were determined using a Zetasizer
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Figure 3 Luciferase expression after transfection of complexes. Complexes were transfected into (A) HepG2 and (B) B16 melanoma cells
and luciferase expression was detected at 24 h after transfection. The results are presented as the RLU per milligram of total protein. Error bars
represent standard deviation of three experiments.
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Figure 4 (A) Change of complex peak area in 10% FBS. Change of light scattering intensity (LSI) (B) and (C) diameter of complex in Opti-
MEM medium. Peak area, diameter, and zeta potential of the complexes were determined using a Zetasizer.
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Page 5 of 7(Malvern Instruments, London, UK) with the He/Ne
laser (633 nm) at a detection angle of 173° and a tem-
perature of 25°C.
Agarose gel electrophoresis
pDNA (0.1 μg) and polymers were mixed in 10 μl
HEPES buffer (10 mM) at several charge ratios. The for-
mulation of complex was assayed by 1% agarose gel
electrophoresis.
Cytotoxicity of complex toward cells
Cell viability was determined using a cell counting kit
containing 4-[3-(2-methoxy-4-nitrophenyl)-2-(4-nitro-
phenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate sodium
salt (WST-8) (Dojindo Laboratories, Kumamoto, Japan).
HepG2 cells were incubated in the absence or presence
of pDNA/PPC (charge ratio = 1:2) or pDNA/PPC/CS
complex (charge ratio = 1:2:16) for 24 h in a 96-well
plate. The conditioned medium in each well was
replaced with 100 μL of fresh medium containing WST-
8, and the cells were incubated for a further 2 h, before
measurement of the absorbance at 440 nm. The cell via-
bility (percent) was calculated by normalizing the absor-
bance of treated cells to that of the untreated control
cells.
Transfection of complexes into cells
Cells (5 × 10
4) were grown in Dulbecco’sm o d i f i e d
Eagle’s medium (DMEM; Gibco Invitrogen Co.) supple-
mented with 10% fetal bovine serum (FBS), 100 U/ml
penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml
amphotericin B (all Gibco). The cells were incubated in
a humidified atmosphere containing 5% CO2 and 95%
air at 37°C for 24 h. After 24 h, the medium was chan-
ged to 500 μL of Opti-MEM (Gibco, Invitrogen Co.),
and pDNA/PPC (charge ratio = 1:2) and pDNA/PPC/CS
(charge ratio = 1:2:16) complexes were added to wells;
concentration of pDNA was 2 μg/well. The cells were
incubated at 37°C for 6 h. After 6 h, the medium was
changed to DMEM, and cells were further incubated for
18 h. The cultured cells were then scraped and lysed in
100 μL of lysis buffer (20 mM Tris-HCl, pH 7.4, 0.05%
Triton-X 100, and 2 mM EDTA). After centrifuging the
sample at 12,000 × g at 4°C for 10 min, a 10 μL aliquot
of the supernatant was used for measuring chemilumi-
nescence in a MiniLumat LB 9506 (EG & G Berthold,
Wildbad, Germany) directly after adding 40 μLo ft h e
luciferin substrate. The results are presented as relative
luminescence units (RLU) per milligram of total protein.
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